Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Sachdeva, Kuldeep Singh ^a   Raizada, Neeraj ^b   Sreenivas, Achuthan ^c   Van't Hoog, Anna H ^d   Van Den Hof, Susan ^d,e   Dewan, Puneet K ^c,g   Thakur, Rahul ^b   Gupta, R S ^a   Kulsange, Shubhangi ^b   Vadera, Bhavin ^b   Babre, Ameet ^b   Gray, Christen ^b   Parmar, Malik ^c   Ghedia, Mayank ^a   Ramachandran, Ranjani ^c   Alavadi, Umesh ^b   Arinaminpathy, Nimalan ^f   Denkinger, Claudia ^b   Boehme, Catharina ^b   Paramasivan, C N ^b  

^a Central TB Division   (India)

^b FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; CASE FINDING; DECENTRALIZATION; DEMOGRAPHY; DRUG RESISTANT TUBERCULOSIS; FEMALE; GEOGRAPHY; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; INCIDENCE; INDIA; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PUBLIC HEALTH SERVICE; SPUTUM SMEAR; TUBERCULOSIS RAPID TEST; YOUNG ADULT; HEALTH SURVEY; MEDICAL GEOGRAPHY; MICROBIAL SENSITIVITY TEST; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GEOGRAPHY, MEDICAL; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; PUBLIC HEALTH SURVEILLANCE; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84930661760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126065     Document Type: Article

References (22)

1. World Health Organization, Geneva, Global Tuberculosis Report, 2013; Available: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656 eng.pdf
2. World Health Organization, Geneva, Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System Policy Statement. 2011; WHO/HTM/TB/2011.4. Available: http://apps.who.int/iris/bitstream/10665/44586/1/9789241501545 eng.pdf?ua=1
3. Steingart R, Sohn H, Schiller I, Kloda A, Boehme C, Pai M, et.al. Xpert MTB/RIF Assay for pulmonary tuberculosis and Rifampicin resistance in adults. Chochrane Database Syst Rev. 2013 Jan 31;1:CD009593. doi: 10.1002/14651858. CD009593.pub2., Available: http://www.ncbi.nlm.nih.gov/pubmed/23440842
4. World health Organization Policy update, Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extra-pulmonary TB in adults and children. Policy Update 2013; WHO/HTM/TB/2013.16. Available: http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335 eng.pdf?ua=1
5. World Health Organization, Geneva, Rapid Implementation of the Xpert MTB/RIF diagnostic test. Technical and Operational 'How-to' Practical Considerations. 2011; WHO/HTM/TB/2011.2. Available: http://whqlibdoc.who.int/publications/2011/9789241501569 eng.pdf
6. Central TB Division Ministry of Health and Family Welfare, New Delhi, India, Revised National TB Control Programme: Tribal Action Plan, 2005; Available: http://tbcindia.nic.in/pdfs/RNTCP%20II%20Tribal %20Action%20Plan 10th%20May%2005.pdf
7. Central TB Division Ministry of Health and Family Welfare, Managing the RNTCP in your area-A training course (Module 1-4). Available: http://tbcindia.nic.in/pdfs/Module%201%20to%204.zip
8. World Health Organization. Geneva Definitions and reporting framework for tuberculosis-2013 revision. 2013; S.n. p. 3. Available: http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345 eng. pdf
9. Central TB Division Ministry of Health and Family Welfare, New Delhi, India, Revised National TB Control Programme, Guidelines on Programmatic Management of Drug ResitantTB (PMDT) in India, 2012; Available: http://tbcindia.nic.in/pdfs/Guidelines%20for%20PMDT%20in%20India%20-%20May% 202012.pdf
10. Central TB Division Ministry of Health and Family Welfare, New Delhi, India, Revised National TB Control Programme: Module for Laboratory Technicians, 2005; Available: http://tbcindia.nic.in/pdfs/Module %20for%20Laboratory%20Technician. pdf
11. Cepheid, Xpert MTB/RIFTwo-hourdetectionof MTB and resistance to rifampicin. Xpert MTB/RIF brochure, 2009;
12. Raizada N, Sachdeva KS, Sreenivas A, Vadera B, Gupta RS, Parmar M, et. al, Feasibility of Decentralised Deploymentof Xpert MTB/RIF Test at Lower Level of Health System in India. PlosOne. 2014; doi: 10.1371/journal.pone.0089301 Available: http://www.plosone.org/article/info%3Adoi%2F10.1371% 2Fjournal.pone.0089301
13. Central TB Division Ministry of Health and Family Welfare, New Delhi, India, Revised National TB Control Programme, Training Manual for Mycobacterium tuberculosis Culture & Drug susceptibility testing: s.n., April, 2009; Available: http://tbcindia.nic.in/pdfs/Training%20manual%20M%20tuberculosis%20C %20DST.pdf
14. Genotype MTBDRPlus Molecular Genetic Assay for Identification of Resistance to Rifampicin and/or Isoniazid of the Mycobacterium tuberculosis Complex. HAIN Lifescience. 2009; pp 23-42 Available: http://www.hain-lifescience.de/en/products/microbiology/mycobacteria/genotype-mtbdrplus.html
15. World Development Indicators, Available: http://data.worldbank.org/country/india; Accessed 16 May 2014.
16. Rath GM, Schnippel K, Long L, MacLeod W, Sanne l, Stevens W, et al. The Impact and Cost of scaling up Xpert MTB/RIF in South Africa.2012; PloSONE. 2012. Vol. 7, 5. E36966, doi: 10.1371/journal. pone.0036966 Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone. 0036966 PMID: 22693561
17. Meeting report From data to scale-up: building the evidence base for new tuberculosis diagnostics. Kuala Lumpur, Malasiya, 2012; Meeting Report. Available: http://www.tbfaqs.org/wp-content/uploads/2013/05/MEETING-REPORT-From-Data-to-Scale-Up-New-TB-Dx2.pdf
18. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, Boon Sd, et al. Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis.2011; PloS Med. 2011. Vol. 8, 11. E1001120. doi: 10.1371/journal.pmed.1001120, Available: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001120 PMID: 22087078
19. National Health Laboratory Service South Africa, GeneXpert MTB/RIF Progress Report, 2012; Available: http://www.nhls.ac.za/assets/files/GeneXpert Update June%20Final.pdf
20. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lisosky M, Bara W, et.al, Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial, The Lancet-1 February 2014, Vol. 383, Issue 9915, Pages 424-435, doi: 10.1016/S0140-6736 (13) 62073-5, Available: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736 (13) 62073-5/fulltext PMID: 24176144
21. Durovni B, Saraceni V, Trajman A, Menezes A, Corderio M, Van Den Hof S, et al. Xpert MTB/RIF pilot roll-out in Brazil: results and lessons learned. Int JTuberc Lung Dis 2013;17(12) Suppl2:S204, Available: http://www.theunion.org/what-we-do/journals/ijtld/body/ABSTRACT BOOK 2013 Web.pdf
22. Dorman S, Chihota V, Lewis J, Shah M, Clark D, Grant AD, etal, Performance Characteristics of the Cepheid Xpert MTB/RIF Test in a Tuberculosis Prevalence Survey, 2012; PLoSOne. 2012;7(8):e43307. Published online 2012 August 15. doi: 10.1371/journal.pone.0043307, PMCID: PMC3419700, Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419700/